NexgenRxNEGXF 51 PB Ratio is 4.45 as of Jul. 04, 2026, which is 7% below its 10-year median of 4.77. GuruFocus rates NEGXF with a GF Score™ of 51/100 and a GF Value™ of $0.27 (Modestly Overvalued). The stock has 6 warning signs investors should review. Among 609 Healthcare Providers & Services companies, NexgenRx ranks worse than 77.83% on this metric.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. As of today (2026-07-04), NexgenRx's share price is $0.325. NexgenRx's Book Value per Share for the quarter that ended in Mar. 2026 was $0.07. Hence, NexgenRx's PB Ratio of today is 4.45.
Warning Sign:
NexgenRx Inc stock PB Ratio (=4.46) is close to 3-year high of 4.76.
The historical rank and industry rank for NexgenRx's PB Ratio or its related term are showing as below:
NEGXF'
s PB Ratio Range Over the Past 10 Years
Min: 2.15 Med: 4.77 Max: 195
Current: 4.46
During the past 13 years, NexgenRx's highest PB Ratio was 195.00. The lowest was 2.15. And the median was 4.77.
NEGXF's PB Ratio is ranked worse than 77.83% of 609
companies
in the Healthcare Providers & Services industry
Industry Median: 1.99
vs NEGXF: 4.46
During the past 12 months, NexgenRx's average Book Value Per Share Growth Rate was 11.00% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was -6.30% per year.
During the past 5 years, the average Book Value Per Share Growth Rate was 2.40% per year.
During the past 13 years, the highest 3-Year average Book Value Per Share Growth Rate of NexgenRx was 64.80% per year. The lowest was -9.90% per year. And the median was 30.15% per year.
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
NexgenRx PB Ratio Related Terms
NexgenRx PB Ratio Historical Data
* Premium members only.
The historical data trend for NexgenRx's PB Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Health Information Services subindustry, NexgenRx's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
NexgenRx PB Ratio vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, NexgenRx's PB Ratio distribution charts can be found below:
* The bar in red indicates where NexgenRx's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
NexgenRx's PB Ratio for today is calculated as follows:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
NexgenRx (NEGXF) has a PB Ratio of 4.45 as of Jul. 04, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on NexgenRx and its competitors. This is near median its historical median of 4.77. Over the past decade, NexgenRx's PB Ratio has ranged from 2.15 to 195.00. According to the industry distribution chart, NexgenRx ranks #474 out of 609 companies in the Healthcare Providers & Services industry, placing it in the top 77.8%.
Is NexgenRx's PB Ratio too high?
NexgenRx's current PB Ratio of 4.45 is near median its 10-year median of 4.77. Over the past 10 years, this metric has ranged from a low of 2.15 to a high of 195.00. The Healthcare Providers & Services industry median PB Ratio is 1.99. NexgenRx's value of 4.45 is 123.6% above this industry median. Based on the distribution chart, NexgenRx ranks #474 out of 609 companies in the Healthcare Providers & Services industry, which is in the bottom quartile relative to peers. Overall, NexgenRx has a GF Score™ of 51/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does NexgenRx's PB Ratio compare to VEEV and BTSG?
According to the Healthcare Providers & Services industry distribution chart, NexgenRx ranks #474 out of 609 companies for PB Ratio. This places NexgenRx in the lower half of its industry. The industry median PB Ratio is 1.99. NexgenRx's value of 4.45 is 123.6% above this benchmark. Historically, NexgenRx's own PB Ratio has ranged from 2.15 to 195.00 over the past decade. While the company's 10-year median is 4.77 vs. the industry median of 1.99, NexgenRx has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Healthcare Providers & Services company?
The median PB Ratio among Healthcare Providers & Services companies is 1.99, based on 609 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. NexgenRx's current PB Ratio of 4.45 is 123.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on NexgenRx and its competitors. For the Healthcare Providers & Services industry, the median PB Ratio is 1.99 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. NexgenRx's current PB Ratio is 4.45, which is near median its own 10-year median of 4.77. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is NexgenRx stock overvalued right now?
Based on GuruFocus' analysis, NexgenRx (NEGXF) is currently considered Modestly Overvalued. The stock's GF Value™ is $0.27, compared to a current price of $0.33 — trading 20.4% above its estimated fair value. The current PB Ratio is 4.45, which is near median its 10-year median of 4.77 and 123.6% above the Healthcare Providers & Services industry median of 1.99. NexgenRx's overall GF Score™ is 51/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For NexgenRx (NEGXF), the current PB Ratio is 4.45 as of Jul. 04, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is NexgenRx (NEGXF) Overvalued in 2026?
Based on GuruFocus' analysis, NexgenRx stock appears to be overvalued.
The current stock price of $0.33 is trading 20.4% above its estimated GF Value™ of $0.27.
GuruFocus considers NexgenRx to be Modestly Overvalued.
Key valuation signals for NEGXF:
PB Ratio: 4.45 (near median its 10-year median of 4.77)
GF Value™: $0.27 vs. price of $0.33 (20.4% above fair value)
Industry Position: 123.6% above the Healthcare Providers & Services median (#474 of 609)
No single metric tells the full story. See the NEGXF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
NexgenRx Inc administers, adjudicates, and pays drug, dental and other extended health-care claims for the beneficiaries of health benefit plans underwritten by its customers using proprietary computer software and also provides ancillary services. The various solutions offered by the company include: NexSys, a fully integrated rules-based adjudication platform for real-time processing of drug, dental, and extended health benefit claims; NexAdmin, which enables sponsors to take complete control of benefit plan administration; and NexPSPAssist, a service that helps Patient Support Programs (PSP) to optimize their deliverables to their manufacturer clients. The company has only one operating segment - benefits administration services.
51GF Score
Get the complete analysis for NEGXF
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NEGXF has been successfully added to your 
